Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbbVie (DE:4AB)
XETRA:4AB
Holding DE:4AB?
Track your performance easily
4AB Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€125.50 - €178.96
Previous Close€176.12
Volume15.00
Average Volume (3M)664.00
Market Cap
€311.34B
Enterprise Value€362.67B
Total Cash (Recent Filing)$13.16B
Total Debt (Recent Filing)$70.63B
Price to Earnings (P/E)63.8
Beta0.06
Next Earnings
Oct 25, 2024EPS Estimate
€2.65Last Dividend Ex-Date
Jul 15, 2024Dividend Yield3.1%
Share Statistics
EPS (TTM)2.76
Shares Outstanding1,766,343,745
10 Day Avg. Volume568
30 Day Avg. Volume664
Standard Deviation0.07
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-4.02
Price to Sales (P/S)6.34
Price to Cash Flow (P/CF)38.40
P/FCF Ratio35.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.59
Enterprise Value/Gross Profit10.70
Enterprise Value/Ebitda20.12
Forecast
1Y Price Target
€175.16Price Target Upside-0.77% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering16
AbbVie News
Bulls Say, Bears Say
Bulls Say
Acquisition ImpactThe recent acquisition of Cerevel and its lead asset Emraclidine is positively impacting the outlook for Abbvie.
Earnings And GuidanceAbbVie beat on both the top and bottom line for the quarter, leading to management raising its 2024 EPS guidance by 1%.
Growth DriversStrong Immunology and Oncology performance, with key drugs like Humira, Rinvoq, Skyrizi, and Imbruvica exceeding consensus estimates.
Bears Say
Drug SalesAbbVie saw misses in Vraylar and its aesthetics business.
Market CompetitionAbbvie is approximately 3+ years behind BMY in launching adjunctive/ADP/other indications, which could limit its market advantage.
Sales PerformanceAesthetics segment sales, including Botox Cosmetic and Juvederm, missed consensus estimates.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.26% Insiders
22.67% Mutual Funds
36.16% Other Institutional Investors
40.90% Public Companies and
Individual Investors
4AB FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was €125.50 and its highest was €178.96 in the past 12 months.
What is AbbVie’s market cap?
Currently, no data Available
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Oct 25, 2024 which is in 61 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Jul 25, 2024. The company reported €2.383 earnings per share for the quarter, beating the consensus estimate of €2.307 by €0.076.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Overvalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of €1.39 which represents an annual dividend yield of 3.1%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is €2.65.
How many shares outstanding does AbbVie have?
AbbVie has 1,766,343,800 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of €2.383 in its last earnings report, beating expectations of €2.307. Following the earnings report the stock price went up 4.594%.
Which hedge fund is a major shareholder of AbbVie?
Among the largest hedge funds holding AbbVie’s share is Diamond Hill Capital Management Inc. It holds AbbVie’s shares valued at 233M.
---
AbbVie Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€175.16 (-0.77% Downside)
€175.16 (-0.77% Downside)
Blogger Sentiment
Bullish
DE:4AB Sentiment 95%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $61.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.50%
12-Months-Change
Fundamentals
Return on Equity
53.93%
Trailing 12-Months
Asset Growth
4.85%
Trailing 12-Months
Company Description
AbbVie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
4AB Earnings Call
Q2 2024
0:00 / 0:00
---
4AB Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
4AB Stock 12 Month Forecast
Average Price Target
€175.16
▼(-0.77% Downside)
Technical Analysis
Best Analysts Covering 4AB
1 Year
1 Year Success Rate
14/14 ratings generated profit
1 Year Average Return
+23.37%
assigned a buy rating last month
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +23.37% per trade.
---